Search research articles
Contact Us
Filters
Showing results (181-190 of 207) with videos related to
Page
of 21
Sort By:
European Urology
|
March 15, 2024
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, et al.
The Lancet. Oncology
|
June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Karim Fizazi, Ken Herrmann, Bernd J Krause, et al.
The Lancet. Oncology
|
August 4, 2019
<sup>18</sup>F-fluciclovine PET-CT and <sup>68</sup>Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Jeremie Calais, Francesco Ceci, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 17, 2025
Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer
Beth K Neilsen, Rong Rong Huang, Luca F Valle, et al.
The Lancet. Oncology
|
July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
JAMA Oncology
|
September 16, 2021
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial
Thomas A Hope, Matthias Eiber, Wesley R Armstrong, et al.
JAMA Oncology
|
March 29, 2019
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 12, 2023
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
Lisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, et al.
European Urology Oncology
|
June 20, 2025
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy
Jesus E Juarez Casillas, John Nikitas, Matthew B Rettig, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 207) with videos related to
Sort By:
Page
of 21
European Urology
|
March 15, 2024
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, et al.
The Lancet. Oncology
|
June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Karim Fizazi, Ken Herrmann, Bernd J Krause, et al.
The Lancet. Oncology
|
August 4, 2019
<sup>18</sup>F-fluciclovine PET-CT and <sup>68</sup>Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Jeremie Calais, Francesco Ceci, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 17, 2025
Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer
Beth K Neilsen, Rong Rong Huang, Luca F Valle, et al.
The Lancet. Oncology
|
July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
JAMA Oncology
|
September 16, 2021
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial
Thomas A Hope, Matthias Eiber, Wesley R Armstrong, et al.
JAMA Oncology
|
March 29, 2019
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 12, 2023
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
Lisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, et al.
European Urology Oncology
|
June 20, 2025
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy
Jesus E Juarez Casillas, John Nikitas, Matthew B Rettig, et al.
Page
of 21